
Neeraj Agarwal, MD, FASCO
@neerajaiims
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI bit.ly/3A3u2KL
ID: 4761682514
https://bit.ly/3JApRJd 15-01-2016 06:32:10
13,13K Tweet
15,15K Followers
770 Following

#AUA23 Amer. Urol. Assn. 👉comparing the complete response (CR) rates of TAR-200 with reported CR rates of Pembrolizumab vs Nadofaregene F👉TAR-200 may become new SOC in near future. Great AE profile. OncoAlert UroToday.com Bladder Cancer Advocacy Network
